CYP2D6 genotype and tamoxifen: Considerations for proper nonprospective studies

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 141-144

  Goetz, M P ^a,b   Ingle, J N ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 INHIBITOR; ENDOXIFEN; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; COLORECTAL CANCER; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENETIC VARIABILITY; GENOTYPE; HUMAN; MEDICAL LITERATURE; METHODOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN;

EID: 84904808627     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.99     Document Type: Review

References (15)

1. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005
2. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007 (Pubitemid 350232249)
3. Regan, M.M. et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J. Natl. Cancer Inst. 104, 441-451 (2012
4. Rae, J.M. et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-Treated breast cancer patients. J. Natl. Cancer Inst. 104, 452-460 (2012
5. Brauch, H., Schroth, W., et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J. Clin. Oncol. 31, 176-180 (2013
6. Goetz, M.P. et al. Re: Concordance between CYP2D6 genotypes obtained from tumorderived and germline DNA. J. Natl. Cancer Inst. (2014), e-pub ahead of print 3 April 2014
7. Ratain, M.J., Nakamura, Y. & Cox, N.J. CYP2D6 genotype and tamoxifen activity: Understanding interstudy variability in methodological quality. Clin. Pharmacol. Ther. 94, 185-187 (2013
8. Goetz, M.P. et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin. Cancer Res. 19, 500-507 (2013
9. Province, M.A. et al. CYP2D6 genotype and adjuvant tamoxifen: Meta-Analysis of heterogeneous study populations. Clin. Pharmacol. Ther. 95, 216-227 (2014
10. Berry, D.A. CYP2D6 genotyping and the use of tamoxifen in breast cancer. J. Natl. Cancer Inst. 105, 1267-1269 (2013
11. Goetz, M.P., Berry, D.A. & Klein, T.E., International Tamoxifen Pharmacogenomics Consortium Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium [abstr 33]. Cancer Res. 69 (suppl. 24), 492s-493s (2009
12. Wu, X., Hawse, J.R., Subramaniam, M., Goetz, M.P., Ingle, J.N. & Spelsberg, T.C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor for degradation in breast cancer cells. Cancer Res. 69, 1722-1727 (2009
13. Stearns, V. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764 (2003 (Pubitemid 38008898)
14. Irvin, W.J. et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J. Clin. Oncol. 29, 3232-3239 (2011
15. Kelly, C.M. et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A populationbased cohort study. BMJ 340, c693 (2010.